A practical reference on visceral adiposity: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-20. Anything still debated is marked as such rather than presented as settled.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue GHRH analog | Sequence matches human GHRH(1-44); differs only at the N-terminus |
| Nominal molecular mass | Approximately 5,136 Da (free base) | Small variation arises from counterion and salt form |
| Appearance | White to off-white lyophilized powder | Supplied in single-use vials intended for reconstitution |
| Solubility class | Freely soluble in water | Practically insoluble in nonpolar organic solvents |
| Typical storage | 2 to 8 degrees Celsius, protected from light | Reconstituted material is handled according to label instructions |
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
=== Applications === The enhanced sensitivity of eSimoa is crucial for early and accurate biomarker detection in clinical diagnostics, facilitating better disease monitoring and management. In drug discovery, the ability to track subtle changes in enzymatic activity aids in the development of more effective pharmaceuticals by providing detailed insights into enzyme inhibition mechanisms.
== Economic impact == Though the many advances of HPLC and monoliths are highly visible within the confines of the analytical and pharmaceutical industries, it is unlikely that general society is aware of these developments. Currently, consumers may witness technology developments in the analytical sciences industry in the form of a broader array of available pharmaceutical products of higher purity, advanced forensic testing in criminal trials, better environmental monitoring, and faster returns on medical tests. In the future, presumably, this may not be the case. As medicine becomes more individualized over time, consumer awareness that something is improving their quality of care seems more likely. The further thought that monoliths or HPLC are involved is unlikely to concern the general public, however. There are two main cost drivers behind technological change in this industry. Though many different analytical areas use LC, including food and beverage industries, forensics labs, and clinical testing facilities, the largest impetus toward technology developments comes from the research and development and production arms of the pharmaceutical industry. The areas in which high-throughput monolithic column technologies are likely to have the largest economic impact are R&D and downstream processing. From the Research and Development field comes the desire for more resolved, faster separations from smaller sample quantities. The only phase of drug development under direct control of a pharmaceutical company is the R&D stage.
Janis, made by Video Arts Television 4 November A Brush with the Greens, about environmental consumer products; the consumer products company Creightons of Billingshurst was looking at developing new products and had an environmental audit by John Elkington; deep ecology; the PA Consulting Group; the Predicasts database; the CEGB wind energy demonstration site in west Wales at Carmarthen Bay Power Station; a million tonnes of plastic packaging waste was caused in the UK each year; separating plastic waste would allow much more recycling of household plastics; the Greater Manchester Waste Disposal Authority; the Purfleet Board plant in Essex, which itself was powered by landfill gas through a Ruston Gas Turbines TB5000 CHP plant, which closed in 2004; a focus group (four women) takes place, where the product designers sit behind a two-way mirror, with new toothpaste designs placed on a mood board. Narrated by wine critic Jancis Robinson, produced by Mike Cockburn, directed by David Sharp, made by London Scientific Films 11 November Patently Obvious?, about acquiring patents in the UK; scenes from the 1951 The Man in the White Suit and The Dam Busters; Barry Fox of New Scientist, and the invention of FM by Edwin Howard Armstrong; Jeremy Phillips of Queen Mary and Westfield College; computer software cannot be patented; Peter Chilvers, who disputed an American patent; the British Technology Group; Richard Taylor and Paul Kellar of Quantel; in the European Patent Organisation, the UK had 6% of patents but the US and Germany had 25% each; Robert Donat in 1951 The Magic Box.
compared to Urey model using reduced partition function ratios. Piasecki et al. performed first-principles calculations of the equilibrium distributions of all substituted isotopologues of methane. The overall conclusion of theoretical studies is
Mohan Singh Kohli (1931–2025), Indian Naval captain and mountaineer who led India's first mission to climb Mount Everest. Virat Kohli (born 5 November 1988) is an Indian International cricketer. Other:
Sources: en.wikipedia.org
== Personal life == Gallrein lives in Shelbyville, Kentucky. He has been married twice. In December 1985, he married Mary E. Stuart. According to court filings, Gallrein filed to divorce his second wife, Heather Gallrein, in 2024 (one month after losing the Kentucky state legislature election). According to court filings, he told her to "get out of his house" and decided to cut her off financially. Gallrein has denied this claim.
Glycated hemoglobin, also called glycohemoglobin, is any form of hemoglobin (Hb) that is chemically linked to a sugar. Most monosaccharides, including glucose, galactose, and fructose, spontaneously (that is, non-enzymatically) bond with hemoglobin when they are present in the bloodstream. However, glucose is only 21% as likely to do so as galactose and 13% as likely to do so as fructose, which may explain why glucose is used as the primary metabolic fuel in humans. The formation of excess sugar-hemoglobin linkages indicates the presence of excessive sugar in the bloodstream and is an indicator of diabetes or other hormone diseases in high concentration (HbA1c > 6.4%). A1c is of particular interest because it is easy to detect. The process by which sugars attach to hemoglobin is called glycation and the reference system is based on HbA1c, defined as beta-N-1-deoxy fructosyl hemoglobin as a component. There are several ways to measure glycated hemoglobin, of which HbA1c (or simply A1c) is a standard single test. HbA1c is measured primarily to determine the three-month average blood sugar level and is used as a standard diagnostic test for evaluating the risk of complications of diabetes and as an assessment of glycemic control. The test is considered a three-month average because the average lifespan of a red blood cell is three to four months. Normal levels of glucose produce a normal amount of glycated hemoglobin. As the average amount of plasma glucose increases, the fraction of glycated hemoglobin increases predictably.
hydroxylation Proline residues may be hydroxylated at either of two atoms, as can lysine (at one atom). Hydroxyproline is a critical component of collagen, which becomes unstable upon its loss. The hydroxylation reaction is catalyzed by an enzyme that requires ascorbic acid (vitamin C), deficiencies in which lead to many connective-tissue diseases such as scurvy. methylation Several protein residues can be methylated, most notably the positive groups of lysine and arginine. Arginine residues interact with the nucleic acid phosphate backbone and commonly form hydrogen bonds with the base residues, particularly guanine, in protein–DNA complexes. Lysine residues can be singly, doubly and even triply methylated. Methylation does not alter the positive charge on the side chain, however. acetylation Acetylation of the lysine amino groups is chemically analogous to the acetylation of the N-terminus. Functionally, however, the acetylation of lysine residues is used to regulate the binding of proteins to nucleic acids. The cancellation of the positive charge on the lysine weakens the electrostatic attraction for the (negatively charged) nucleic acids. sulfation Tyrosines may become sulfated on their
=== United States === In the United States, the Controlled Substances Act of 1970 classified most barbiturates as controlled substances; Barbital, mephobarbital, and phenobarbital are designated schedule IV drugs. Additionally, and "Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid" which includes the oxygenated, methylated, and brominated of compounds like enallylprypam) were designated as being schedule III. Under the original CSA, no barbiturates were placed in schedule I, II, or V; however, amobarbital, pentobarbital, and secobarbital are now schedule II controlled substances unless they are in a suppository dosage form. In 1971, the Convention on Psychotropic Substances was signed in Vienna. Designed to regulate amphetamine and various synthetics compounds, the 34th version of the treaty regulates secobarbital as schedule II, amobarbital, butalbital, cyclobarbital, and pentobarbital as schedule III, and allobarbital, barbital, butobarbital, mephobarbital, phenobarbital, butabarbital, and vinylbital as schedule IV on its "Green List". The combination medication Fioricet, consisting of butalbital, caffeine, and paracetamol (acetaminophen), however, is specifically exempted from controlled substance status, while its sibling Fiorinal, which contains aspirin instead of paracetamol and may contain codeine phosphate, remains a schedule III drug.
Sources: en.wikipedia.org
Sixty common starlings were released in 1890 into New York's Central Park by Eugene Schieffelin, but there is no evidence that he was trying to introduce every bird species mentioned in the works of William Shakespeare into North America. This claim has been traced to an essay in 1948 by naturalist Edwin Way Teale, whose notes appear to indicate that it was speculation.
== Medical uses == Desloratadine is used to treat allergic rhinitis, nasal congestion and chronic idiopathic urticaria (hives). It is the major metabolite of loratadine and the two drugs are similar in safety and effectiveness. Desloratadine is available in many dosage forms and under many brand names worldwide. An emerging indication for desloratadine is in the treatment of acne, as an inexpensive adjuvant to isotretinoin and possibly as maintenance therapy or monotherapy.
The Ainu people inhabited the Kuril Islands from early times, although few records predate the 17th century. From the Kamakura period to the Muromachi period, there were Ezo (Ainu) people called Hinomoto from the Pacific coast of Hokkaido to the Kuril region, and Mr. Ando, the Ezo Sateshiku and Ezo Kanrei, was in charge of this ("Suwa Daimyojin Ekotoba"). It is said that when turmoil broke out on Ezogashima, he dispatched troops from Tsugaru. Its activities include the Kanto Gomensen, which calls itself the Ando Suigun, and is based in Jusanminato ("Kaisen Shikimoku"), supplying Japanese products to Ezo society and purchasing large quantities of northern products and shipping them nationwide. ("Thirteen Streets"). The Matsumae clan, a feudal lord of Japan, became independent from the Ando clan (the family of Goro Ando). The Japanese administration first took nominal control of the islands during the Edo period (1603–1868) in the form of claims by the Matsumae clan. The Shōhō Era Map of Japan (Shōhō kuni ezu (正保国絵図)), a map of Japan made by the Tokugawa shogunate in 1644, shows 39 large and small islands northeast of Hokkaido's Shiretoko Peninsula and Cape Nosappu. A Dutch expedition under Maarten Gerritsz Vries explored the islands in 1643. Fedot Alekseyevich Popov sailed into the area c. 1649. Russian Cossacks landed on Shumshu in 1711. American whaleships caught right whales off the islands between 1847 and 1892. Three such ships were wrecked on the islands: two on Urup in 1855 and one on Makanrushi in 1856.
Sources: en.wikipedia.org
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.
No. It is a releasing-factor analog that signals the pituitary gland to secrete growth hormone, whereas recombinant growth hormone is the hormone itself administered directly. The two are chemically distinct and act at different points in the same endocrine pathway. This distinction is often lost in informal discussion.
Native growth hormone-releasing hormone is broken down within minutes by dipeptidyl peptidase-4 in the bloodstream. Adding the hexenoyl group at the N-terminus shields the peptide from that enzyme. The modification does not change the receptor it targets, only how long the peptide survives in circulation.
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.